A Multicentric, Open label, Randomized, Comparative, Parallel-group, Active-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety of oral tablets of Fixed-dose Combination of Cefpodoxime 200 mg and Ofloxacin 200 mg in Comparison with Cefpodoxime 200 mg alone in patients with respiratory tract infection [RTI] and typhoid fever.

Trial Profile

A Multicentric, Open label, Randomized, Comparative, Parallel-group, Active-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety of oral tablets of Fixed-dose Combination of Cefpodoxime 200 mg and Ofloxacin 200 mg in Comparison with Cefpodoxime 200 mg alone in patients with respiratory tract infection [RTI] and typhoid fever.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Cefpodoxime; Cefpodoxime/ofloxacin
  • Indications Respiratory tract infections; Typhoid
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
    • 20 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top